blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2155237

EP2155237 - GLYCOSYLASPARAGINASE FOR TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2010/08]METHOD FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES
[2015/41]
StatusNo opposition filed within time limit
Status updated on  16.12.2016
Database last updated on 25.09.2024
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): MT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
Oy Reagena Ltd
Takojantie 18
70900 Toivala / FI
[2010/08]
Inventor(s)01 / MONONEN, Ilkka
Kupittaankatu 40
FI-20700 Turku / FI
02 / KELO, Eira
Rissalantie 33 a 3
FI-70910 Vuorela / FI
 [2010/08]
Representative(s)(deleted)
[N/P]
Former [2016/06]Öhman, Ann-Marie
Kaivokatu 15 B 23
20520 Turku / FI
Former [2010/08]Öhman, Ann-Marie
Kaivokatu 15 B 23
20520 Turku / FI
Application number, filing date08761679.320.05.2008
[2010/08]
WO2008FI50283
Priority number, dateFI2007000045508.06.2007         Original published format: FI 20070455
US20070942721P08.06.2007         Original published format: US 942721 P
[2010/08]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008148932
Date:11.12.2008
Language:EN
[2008/50]
Type: A2 Application without search report 
No.:EP2155237
Date:24.02.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 11.12.2008 takes the place of the publication of the European patent application.
[2010/08]
Type: B1 Patent specification 
No.:EP2155237
Date:10.02.2016
Language:EN
[2016/06]
Search report(s)International search report - published on:EP19.02.2009
ClassificationIPC:A61K38/50, A61P35/00, A61P29/00, C12N9/82
[2015/41]
CPC:
A61K38/50 (EP,US); A61P29/00 (EP); A61P35/00 (EP);
A61P35/04 (EP); C12N9/82 (EP,US)
Former IPC [2010/08]A61K38/50, A61P35/00, A61P29/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/06]
Former [2010/08]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:GLYKOSYLASPARAGINASE ZUR BEHANDLUNG VON KREBS[2015/41]
English:GLYCOSYLASPARAGINASE FOR TREATMENT OF CANCER[2015/41]
French:GLYCOSYLASPARAGINASE POUR LE TRAITEMENT DE CANCERS[2015/41]
Former [2010/08]VERFAHREN ZUR BEHANDLUNG VON KREBS- ODER ENTZÜNDUNGSERKRANKUNGEN
Former [2010/08]METHOD FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES
Former [2010/08]PROCÉDÉ POUR LE TRAITEMENT DE CANCERS OU DE MALADIES INFLAMMATOIRES
Entry into regional phase26.10.2009National basic fee paid 
26.10.2009Designation fee(s) paid 
26.10.2009Examination fee paid 
Examination procedure26.10.2009Examination requested  [2010/08]
17.07.2014Despatch of a communication from the examining division (Time limit: M04)
12.09.2014Reply to a communication from the examining division
23.06.2015Despatch of a communication from the examining division (Time limit: M04)
31.08.2015Reply to a communication from the examining division
27.10.2015Communication of intention to grant the patent
19.11.2015Fee for grant paid
19.11.2015Fee for publishing/printing paid
26.11.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.07.2014
Opposition(s)11.11.2016No opposition filed within time limit [2017/03]
Fees paidRenewal fee
18.03.2010Renewal fee patent year 03
28.03.2011Renewal fee patent year 04
08.05.2012Renewal fee patent year 05
22.04.2013Renewal fee patent year 06
06.05.2014Renewal fee patent year 07
16.04.2015Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.05.2008
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
PL10.02.2016
RO10.02.2016
SI10.02.2016
SK10.02.2016
TR10.02.2016
BG10.05.2016
NO10.05.2016
GR11.05.2016
LU20.05.2016
MT31.05.2016
IS10.06.2016
PT13.06.2016
[2018/32]
Former [2018/29]HU20.05.2008
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
PL10.02.2016
RO10.02.2016
SI10.02.2016
SK10.02.2016
TR10.02.2016
BG10.05.2016
NO10.05.2016
GR11.05.2016
LU20.05.2016
IS10.06.2016
PT13.06.2016
Former [2018/28]HU20.05.2008
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
PL10.02.2016
RO10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
NO10.05.2016
GR11.05.2016
LU20.05.2016
IS10.06.2016
PT13.06.2016
Former [2017/15]AT10.02.2016
BE10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
RO10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
NO10.05.2016
GR11.05.2016
LU20.05.2016
IS10.06.2016
PT13.06.2016
Former [2017/04]AT10.02.2016
BE10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
RO10.02.2016
SK10.02.2016
NO10.05.2016
GR11.05.2016
LU20.05.2016
IS10.06.2016
PT13.06.2016
Former [2017/03]AT10.02.2016
BE10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
RO10.02.2016
SK10.02.2016
NO10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/50]AT10.02.2016
CZ10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
RO10.02.2016
SK10.02.2016
NO10.05.2016
GR11.05.2016
BE31.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/49]AT10.02.2016
EE10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
NO10.05.2016
GR11.05.2016
BE31.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/39]AT10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
LV10.02.2016
PL10.02.2016
NO10.05.2016
GR11.05.2016
BE31.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/38]AT10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
PL10.02.2016
NO10.05.2016
GR11.05.2016
BE31.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/36]AT10.02.2016
ES10.02.2016
HR10.02.2016
IT10.02.2016
LT10.02.2016
PL10.02.2016
NO10.05.2016
GR11.05.2016
BE31.05.2016
Former [2016/35]ES10.02.2016
HR10.02.2016
NO10.05.2016
GR11.05.2016
Cited inInternational search[A]US4617271  (NAMBU MASAO [JP]) [A] 1-10,1-10,1-10 * claims; column 1, line 8 - line 15 * * claims; column 1, line 8 - line 15 * * claims; column 1, line 8 - line 15 *;
 [A]EP0811687  (HAYASHIBARA BIOCHEM LAB [JP]) [A] 1-10,1-10,1-10 * page 2, line 3 - line 4 * * page 25, line 1 - line 13; table 8 * * claims * * page 2, line 3 - line 4 * * page 25, line 1 - line 13; table 8 * * claims * * page 2, line 3 - line 4 * * page 25, line 1 - line 13; table 8 * * claims *;
 [A]US6251388  (DURDEN DONALD L [US]) [A] 1-10,1-10,1-10 * claims; column 8, line 54 - column 9, line 11 * * claims; column 8, line 54 - column 9, line 11 * * claims; column 8, line 54 - column 9, line 11 *;
 [AD]WO03038113  (MILLENNIUM PHARM INC [US], et al) [AD] 1-10,1-10,1-10 * claims; page 2, line 14 - page 4, line 3 * * claims; page 2, line 14 - page 4, line 3 * * claims; page 2, line 14 - page 4, line 3 *;
 [AD]US2004197299  (DELATTRE CAROLINE [FR], et al) [AD] 1-10,1-10,1-10 * claims; paragraphs [0018] - [0021] * * claims; paragraphs [0018] - [0021] * * claims; paragraphs [0018] - [0021] *;
 [A]  - YLIKANGAS PAIVI ET AL, "Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation", THERAPEUTIC DRUG MONITORING, (200208), vol. 24, no. 4, ISSN 0163-4356, pages 502 - 506, XP009109534 [A] 1-10,1-10,1-10 * abstract * * abstract * * abstract *

DOI:   http://dx.doi.org/10.1097/00007691-200208000-00007
 [A]  - REIFF A ET AL, "Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase.", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2001 NOV-DEC, (200111), vol. 19, no. 6, ISSN 0392-856X, pages 639 - 646, XP009109566 [A] 1-10,1-10,1-10 * abstract * * page 640, column L, paragraph L - column R, paragraph 2 * * abstract * * page 640, column L, paragraph L - column R, paragraph 2 * * abstract * * page 640, column L, paragraph L - column R, paragraph 2 *
 [DA]  - KAARTINEN V ET AL, "SUBSTRATE SPECIFICITY AND REACTION MECHANISM OF HUMAN GLYCOASPARAGINASE THE N-GLYCOSIDIC LINKAGE OF VARIOUS GLYCOASPARAGINES IS CLEAVED THROUGH A REACTION MECHANISM SIMILAR TO L ASPARAGINASE", JOURNAL OF BIOLOGICAL CHEMISTRY, (1992), vol. 267, no. 10, ISSN 0021-9258, pages 6855 - 6858, XP002506519 [DA] 1-10,1-10,1-10 * abstract * * abstract * * abstract *
Examination   - Dominika Borek ET AL, "Expression, purification and catalytic activity of Lupinus luteus asparagine [beta]-amidohydrolase and its Escherichia coli homolog", European Journal of Biochemistry, GB, (20040714), vol. 271, no. 15, doi:10.1111/j.1432-1033.2004.04254.x, ISSN 0014-2956, pages 3215 - 3226, XP055188258

DOI:   http://dx.doi.org/10.1111/j.1432-1033.2004.04254.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.